Our aim was therefore to investigate if treatment with peanut OIT (pOIT) in combination with omalizumab improves self-reported HRQoL among adolescents with severe peanut allergy. To measure HRQoL, the food allergy questionnaire Food Allergy Quality of Life Questionnaire-Teenager Form (FAQLQ-TF) was used. Peanut allergy is one of the major food allergies, and has an impact on the health-related quality of life (HRQoL).[1] As for today there is no curative treatment, however guidelines recommend oral immunotherapy (OIT) as a therapeutic option to increase the threshold for reactions in children with persistent peanut allergy.[[2]] In line with the guidelines, measurements of treatment effect should include patient-reported outcomes such as HRQoL. [Extracted from the article]